Latest 10-Q quarterly reports

Trimble Inc. reported a net loss of $471.7 million for the second quarter of 2026, largely due to a $562.0 million goodwill impairment charge, despite an 11% increase in total revenue.

Acumen Pharmaceuticals reported a net loss of $32.7 million for Q2 2026 and highlighted substantial doubt about its ability to continue as a going concern, despite advancing its Alzheimer's disease drug candidates.

Omeros Corporation's Q2 2026 Form 10-Q highlights robust YARTEMLEA sales growth and positive pipeline advancements, alongside a significant repurchase of convertible notes.

Talphera, Inc. reported a net loss of $4.3 million for Q2 2026, with cash reserves dwindling, raising concerns about its ability to fund operations beyond the next twelve months.

Sera Prognostics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses, increased operating expenses, and strategic workforce reductions alongside positive clinical study results and expanded partnerships.

BioCardia, Inc. reported continued clinical development progress for its cell therapies but highlighted significant going concern issues due to insufficient cash reserves beyond January 2027.

Willow Lane Acquisition Corp. II reports net income for Q2 2026 driven by trust account interest, with no operating revenue as it continues to search for a business combination target.

SKYX Platforms Corp. announced its second quarter 2026 financial results, showing a 9.7% increase in revenue to $47.4 million for the six months ended June 30, 2026, while net loss narrowed slightly.

Kairos Pharma, Ltd. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development activities alongside significant financial challenges and substantial doubt regarding its ability to continue as a going concern.

Decoy Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing ongoing operational losses, a significant cash burn, and a new risk of Nasdaq delisting.

Yorkville Acquisition Corp. has terminated its business combination agreement due to market conditions and faces substantial doubt regarding its ability to continue as a going concern.

WisdomTree Bitcoin Fund (BTCW) reported a significant decrease in Net Asset Value per Share and substantial unrealized losses for the quarter ended June 30, 2026, driven by Bitcoin price depreciation.

QT Imaging Holdings, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in revenue driven by scanner sales, but also reporting substantial net losses and rising operating costs.

Gaxos.ai Inc. filed its Q2 2026 Form 10-Q, showing a substantial increase in revenues driven by administrative services and subscriptions, but also a significant rise in operating expenses and a net loss attributable to common shareholders.

Armada Acquisition Corp. III (AACI) filed its Form 10-Q for the quarter ended June 30, 2026, detailing its financial position post-IPO and ongoing efforts to identify a business combination.

VivoSim Labs, Inc. reported a net loss of $1.3 million for the quarter ended June 30, 2026, with significant cash burn and substantial doubt about its going concern status, despite a recent capital raise.

Toppoint Holdings Inc. announced a 17% increase in Q2 2026 revenue to $4.64 million, driven by import and metal transport, alongside improved gross margins, though net loss persisted.

Nixxy, Inc. filed its Q2 2026 10-Q, detailing revenue growth in its telecommunications segment but highlighting significant net losses and substantial doubt regarding its ability to continue as a going concern.

ABVC BioPharma reported continued net losses and a working capital deficit in its Q2 2026 filing, raising substantial doubt about its going concern status.

Jerash Holdings (US), Inc. announced a 27% year-over-year revenue increase for the second quarter ended June 30, 2026, driven by strong U.S. sales and new customer acquisition.

Bluejay Diagnostics reports increased R&D spending and continued net losses in its Q2 2026 filing, highlighting a critical need for further capital to fund operations through mid-2027.

Acrivon Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical development of ACR-368 and ACR-2316, alongside significant operating losses and a projected need for additional funding.

Knightscope, Inc. reported a significant increase in Q2 revenue driven by its acquisition of Knightscope Security Force, but continued to incur substantial net losses, raising concerns about its going concern status.

STAAR Surgical Company's Q2 2026 results show a significant increase in net sales and a return to net income, driven by strong performance in China and improved gross margins.

Range Impact, Inc. reported a net loss of $1.86 million for Q2 2026, an increase from the prior year, with revenues remaining flat.

EGH Acquisition Corp. reports on its Q2 2026 financial status, highlighting continued preparations for the Hecate Business Combination, which is now anticipated for Q4 2026, and addressing ongoing legal matters.

Nano Nuclear Energy Inc. details advancements in microreactor development and strategic acquisitions, while highlighting substantial capital requirements for future commercialization.

Bank of the James Financial Group, Inc. announced a significant increase in net income for the six months ended June 30, 2026, driven by higher net interest income and noninterest income, alongside reduced noninterest expenses.

Altimmune reports substantial progress in its late-stage clinical trials for MASH and AUD, bolstered by a significant $211 million capital raise, while continuing to manage operational losses.

BayFirst Financial Corp. has filed an amended 10-Q report to restate its financial statements for the quarter ended March 31, 2026, citing material weaknesses in internal controls and accounting errors.